Hülya Bilgen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Hülya Bilgen has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Kursat Ozdilli
Department of Medical Biology, Faculty of Medicine, Istanbul Medipol University, Istanbul 34810, Turkey
2 shared publications - Murat Elli
Department of Pediatric Hematology and Oncology, İstanbul Medipol University, İstanbul, Turkey
2 shared publications - Nihan Bayram
Pediatric Hematology and Oncology
2 shared publications - Sema Anak
Pediatric Bone Marrow Transplantation Unit, Istanbul Medipol University, Bagcilar, Istanbul, Turkey
2 shared publications - Serdar Nepesov
Department of Pediatric Immunology and Allergy, School of Medicine, Istanbul University-Cerrahpaşa, Fatih Istanbul, Türkiye
2 shared publications - Yöntem Yaman
Department of Pediatric Hematology, Medipol University Faculty of Medicine, Istanbul, Türkiye
2 shared publications
Latest Publications
- Open Access
- 14 March 2026
- Published by Elsevier in SSRN Electronic Journal
Blood Donation Surge, Transfusion Demand, and Component Wastage after a Major Earthquake: A Three-year Analysis from a Tertiary Trauma Center
Following mass casualty disasters, blood collection activity increases in response to anticipated transfusion needs. However, this donation surge may be misaligned with clinical demands potentially increasing outdating and other forms of wastage. Evidence describing how trauma centers absorb transfusion demand while managing inventory losses in mass casuality incidents. This study evaluates changes in blood product issuance and wastage in a referral trauma center before, during, and after February 6, 2023 Kahramanmaraş Earthquake.We performed a three-year retrospective analysis of daily issue and wastage of five blood components between January 1, 2022 and December 31, 2024. Comparisons of wastage rates were made across three predefined periods (pre-earthquake, earthquake, post-earthquake), with wastage as percentage of issue calculated as aggregated estimates and weekly overalls.During the earthquake period, median daily erytrocyte suspension issuance increased by 19.7% compared with the pre-earthquake period (154 vs 127 units/day; p<0.001), without a proportional rise in expiration losses (0.2% vs 0.4%; p=0.240) . Platelet wastage decreased during the earthquake period by 7.3% for apheresis suspension, 13.9% for pooled concentrates which are consistent with faster stock turnover. In contrast, all-cause wastage of fresh frozen plasma increased across periods from 4.6% to 5.0% and 6.1% eventually.In this non-epicentral tertiary trauma center, disaster-associated increases in blood product use did not uniformly amplify wastage and were component-specific. Increased turnover during the earthquake period coincided with reduced platelet wastage, whereas fresh frozen plasmawastage rose and may reflect structural inventory factors. Period-level aggregated wastage rates provides robust benchmarking for disaster preparedness assessments especially for low-volume products.
- 14 March 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessBlood Donation Surge, Transfusion Demand, and Component Wastage after a Major Earthquake: A Three-year Analysis from a Tertiary Trauma Center
Following mass casualty disasters, blood collection activity increases in response to anticipated transfusion needs. However, this donation surge may be misaligned with clinical demands potentially increasing outdating and other forms of wastage. Evidence describing how trauma centers absorb transfusion demand while managing inventory losses in mass casuality incidents. This study evaluates changes in blood product issuance and wastage in a referral trauma center before, during, and after February 6, 2023 Kahramanmaraş Earthquake.We performed a three-year retrospective analysis of daily issue and wastage of five blood components between January 1, 2022 and December 31, 2024. Comparisons of wastage rates were made across three predefined periods (pre-earthquake, earthquake, post-earthquake), with wastage as percentage of issue calculated as aggregated estimates and weekly overalls.During the earthquake period, median daily erytrocyte suspension issuance increased by 19.7% compared with the pre-earthquake period (154 vs 127 units/day; p<0.001), without a proportional rise in expiration losses (0.2% vs 0.4%; p=0.240) . Platelet wastage decreased during the earthquake period by 7.3% for apheresis suspension, 13.9% for pooled concentrates which are consistent with faster stock turnover. In contrast, all-cause wastage of fresh frozen plasma increased across periods from 4.6% to 5.0% and 6.1% eventually.In this non-epicentral tertiary trauma center, disaster-associated increases in blood product use did not uniformly amplify wastage and were component-specific. Increased turnover during the earthquake period coincided with reduced platelet wastage, whereas fresh frozen plasmawastage rose and may reflect structural inventory factors. Period-level aggregated wastage rates provides robust benchmarking for disaster preparedness assessments especially for low-volume products.
- 1 January 2024
- Published by Springer Nature
- p. 39-45
How to Read ASFA Guideline
- Open Access
- 30 April 2022
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 24 (1) , 90-94
The Relationship of Body Mass Index with Platelet Counts and Donation Frequency of Platelet Apheresis Donors
Aim: The aim of this study was to investigate the demographic characteristics of platelet apheresis donors during the coronavirus disease 2019 (COVID-19) pandemic, to examine the association of platelet counts with blood groups and body mass index (BMI), and to characterize the effects of BMI on platelet apheresis donation. Material and Methods: In this retrospective study, the demographic characteristics of platelet apheresis donors admitted to our center between January 2020 and January 2021 were examined, and hemogram parameters, previous platelet donation frequencies, and blood groups information were recorded. The relationship between donors' platelet counts, blood groups, and BMI were analyzed. Results: There was no statistically significant relationship between the platelet counts and blood groups. Although platelet counts were higher in Rh positive donors, no statistically significant relationship was found between platelet counts and the Rh group (p=0.675). Even though the platelet counts were lower in low-weight donors, there was no statistically significant relationship between platelet count and BMI groups (p=0.134). The lower collected platelet counts of the normal group, compared to the obese group, was found to be statistically significant (p=0.001). The number of donations for the overweight group being higher than the normal and obese groups was found to be statistically significant (p=0.002). Conclusion: Even though the platelet count increases with obesity, it does not have any statistical significance in healthy platelet donors. In conclusion, obesity does not have an inverse relationship with platelet apheresis donation and high BMI should not be considered as a prognostic factor for donation.
- 30 April 2022
- Published by Duzce Medical Journal in Düzce Tıp Fakültesi Dergisi
- Vol. 24 (1) , 90-94
Open AccessThe Relationship of Body Mass Index with Platelet Counts and Donation Frequency of Platelet Apheresis Donors
Aim: The aim of this study was to investigate the demographic characteristics of platelet apheresis donors during the coronavirus disease 2019 (COVID-19) pandemic, to examine the association of platelet counts with blood groups and body mass index (BMI), and to characterize the effects of BMI on platelet apheresis donation. Material and Methods: In this retrospective study, the demographic characteristics of platelet apheresis donors admitted to our center between January 2020 and January 2021 were examined, and hemogram parameters, previous platelet donation frequencies, and blood groups information were recorded. The relationship between donors' platelet counts, blood groups, and BMI were analyzed. Results: There was no statistically significant relationship between the platelet counts and blood groups. Although platelet counts were higher in Rh positive donors, no statistically significant relationship was found between platelet counts and the Rh group (p=0.675). Even though the platelet counts were lower in low-weight donors, there was no statistically significant relationship between platelet count and BMI groups (p=0.134). The lower collected platelet counts of the normal group, compared to the obese group, was found to be statistically significant (p=0.001). The number of donations for the overweight group being higher than the normal and obese groups was found to be statistically significant (p=0.002). Conclusion: Even though the platelet count increases with obesity, it does not have any statistical significance in healthy platelet donors. In conclusion, obesity does not have an inverse relationship with platelet apheresis donation and high BMI should not be considered as a prognostic factor for donation.
- 16 April 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (4) , e14024
Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome‐like Relapsed/Refractory acute lymphoblastic leukemia
Introduction: (Ph‐like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR‐ABL1 translocation.Case description: We reported an exceptional case of a child with relapsed Ph‐like ALL with IKZF1 gene deletion treated with high‐dose ruxolitinib as monotherapy, after multi‐agent chemotherapy. He remains in continued MRD‐negative leukemia remission with full donor chimerism at 12 months post‐HSCT.Discussion: The circumstance that makes our case featured is the usage of ruxolitinib as monotherapy. This report, we believe, is a pioneering report for a frequent disease with a high risk of failure for the outcome.
- 16 April 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (4) , e14024
Clinical Efficacy of Ruxolitinib Monotherapy and Haploidentical Hematopoeitic Stem Cell Transplantation in a Child with Philadelphia Chromosome‐like Relapsed/Refractory acute lymphoblastic leukemia
Introduction: (Ph‐like) ALL is a subset of leukemia which has a gene expression profile similar to Ph+disease, but without the presence of BCR‐ABL1 translocation.Case description: We reported an exceptional case of a child with relapsed Ph‐like ALL with IKZF1 gene deletion treated with high‐dose ruxolitinib as monotherapy, after multi‐agent chemotherapy. He remains in continued MRD‐negative leukemia remission with full donor chimerism at 12 months post‐HSCT.Discussion: The circumstance that makes our case featured is the usage of ruxolitinib as monotherapy. This report, we believe, is a pioneering report for a frequent disease with a high risk of failure for the outcome.
- 16 January 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (5) , e13962
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single‐centre experience
Delayed recovery of thrombocytopenia is a well‐known complication after allogeneic HSCT. Eltrombopag (ELT), a thrombopoietin receptor agonist (TRAs), induces platelet maturation and release. Mostly conducted in adults, some of the previous studies have shown that ELT seems to enhance platelet recovery for post‐allogeneic HSCT thrombocytopenia, appears efficacious, and offers transfusion independence. To evaluate the safety and efficacy of ELT in pediatric patients with prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) after alloHSCT. Retrospective analysis of childhood patients who received treatment with ELT for persistent thrombocytopenia after alloHSCT between May 2016 and August 2019. We evaluated the safety and efficacy of ELT in 18 childhood patients with PIT or SFPR after alloHSCT. Eltrombopag (50 mg/d) treatment was started in all patients, above 6 years of age and 20 kg weight, who had thrombocytopenia despite neutrophil engraftment on the 30th day of HSCT. Our objective was to decrease the need for platelet transfusion and have a platelet count of more than 50 000/µL. The overall response rate was 77.7%. The median time to achieve a platelet level above 30 000/µL and 50 000/µL was 21 and 44 days, respectively. In four patients, platelet count never reached 30 000/mm3. In two patients, the treatment was discontinued due to grade 3 hepatotoxicity. Our study supports the efficacy and relative safety of ELT use for the treatment of PIT and SFPR seen after alloHSCT in children.
- 16 January 2021
- Published by Wiley in Pediatric Transplantation
- Vol. 25 (5) , e13962
Eltrombopag for treatment of thrombocytopenia after allogeneic hematopoietic cell transplantation in children: Single‐centre experience
Delayed recovery of thrombocytopenia is a well‐known complication after allogeneic HSCT. Eltrombopag (ELT), a thrombopoietin receptor agonist (TRAs), induces platelet maturation and release. Mostly conducted in adults, some of the previous studies have shown that ELT seems to enhance platelet recovery for post‐allogeneic HSCT thrombocytopenia, appears efficacious, and offers transfusion independence. To evaluate the safety and efficacy of ELT in pediatric patients with prolonged isolated thrombocytopenia (PIT) or secondary failure of platelet recovery (SFPR) after alloHSCT. Retrospective analysis of childhood patients who received treatment with ELT for persistent thrombocytopenia after alloHSCT between May 2016 and August 2019. We evaluated the safety and efficacy of ELT in 18 childhood patients with PIT or SFPR after alloHSCT. Eltrombopag (50 mg/d) treatment was started in all patients, above 6 years of age and 20 kg weight, who had thrombocytopenia despite neutrophil engraftment on the 30th day of HSCT. Our objective was to decrease the need for platelet transfusion and have a platelet count of more than 50 000/µL. The overall response rate was 77.7%. The median time to achieve a platelet level above 30 000/µL and 50 000/µL was 21 and 44 days, respectively. In four patients, platelet count never reached 30 000/mm3. In two patients, the treatment was discontinued due to grade 3 hepatotoxicity. Our study supports the efficacy and relative safety of ELT use for the treatment of PIT and SFPR seen after alloHSCT in children.
- Open Access
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1781-1785
A single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma
Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was previously used successfully to treat SARS-CoV-1 and MERS infections. Health authority in Turkey has published a guideline to integrate this promising option in the treatment process of patients who are prone to high risk of developing severe COVID-19. Materials and Methods: Forty consecutive patients who had received CP at our center were included in the study. Demographics, COVID-19 specific parameters, biomarkers to detect the severity of COVID-19 infection and outcome variables were collected retrospectively. The correlation between outcome variables and the independent predictors of the outcome were reported. Results: Median age of the patients was 57.5 and 72.5% were male. At least one COVID-19 PCR test was confirmed to be positive in 75% of patients. Remaining 25% had a Chest-CT which was reported to be compatible with an ongoing COVID-19. All patients (100%) were classified as having severe COVID-19 infection. Over a half of the patients harbored an oxygen saturation of less than 90 despite of a continuous 5 L/min support of O-2. 82.5% of the patients had a need for mechanical ventilation and 45.5% had a need for invasive mechanical ventilation. Nine out of 10 patients who have received CP outside ICU have totally recovered from COVID-19 at a median of 9 days, and a half of the patients who needed invasive mechanical ventilation were successfully free of mechanical ventilation support and managed to recover from COVID-19. Conclusion: According to the results of this study, CP is an efficient conjunct to conventional therapy against COVID-19 with a favorable safety profile.
- 17 December 2020
- Published by The Scientific and Technological Research Council of Turkey (TUBITAK-ULAKBIM) - DIGITAL COMMONS JOURNALS in TURKISH JOURNAL OF MEDICAL SCIENCES
- Vol. 50 (8) , 1781-1785
Open AccessA single center cohort of 40 severe COVID-19 patients who were treated with convalescent plasma
Background/aim: A SARS-Cov2 infection which was first arised from Wuhan in December 2019 and named as COVID-19. Still there lacks either a specific treatment or a vaccine to treat COVID-19. Convalescent plasma (CP) was previously used successfully to treat SARS-CoV-1 and MERS infections. Health authority in Turkey has published a guideline to integrate this promising option in the treatment process of patients who are prone to high risk of developing severe COVID-19. Materials and Methods: Forty consecutive patients who had received CP at our center were included in the study. Demographics, COVID-19 specific parameters, biomarkers to detect the severity of COVID-19 infection and outcome variables were collected retrospectively. The correlation between outcome variables and the independent predictors of the outcome were reported. Results: Median age of the patients was 57.5 and 72.5% were male. At least one COVID-19 PCR test was confirmed to be positive in 75% of patients. Remaining 25% had a Chest-CT which was reported to be compatible with an ongoing COVID-19. All patients (100%) were classified as having severe COVID-19 infection. Over a half of the patients harbored an oxygen saturation of less than 90 despite of a continuous 5 L/min support of O-2. 82.5% of the patients had a need for mechanical ventilation and 45.5% had a need for invasive mechanical ventilation. Nine out of 10 patients who have received CP outside ICU have totally recovered from COVID-19 at a median of 9 days, and a half of the patients who needed invasive mechanical ventilation were successfully free of mechanical ventilation support and managed to recover from COVID-19. Conclusion: According to the results of this study, CP is an efficient conjunct to conventional therapy against COVID-19 with a favorable safety profile.